Compare LRN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | LEGN |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 5.9B |
| IPO Year | 2007 | 2020 |
| Metric | LRN | LEGN |
|---|---|---|
| Price | $87.56 | $17.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $106.75 | $63.08 |
| AVG Volume (30 Days) | 714.0K | ★ 1.5M |
| Earning Date | 04-28-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.87 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $917,734,000.00 | N/A |
| Revenue This Year | $6.18 | $46.27 |
| Revenue Next Year | $4.74 | $28.77 |
| P/E Ratio | $25.02 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $16.24 |
| 52 Week High | $171.17 | $45.30 |
| Indicator | LRN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 42.22 |
| Support Level | $79.83 | $17.46 |
| Resistance Level | $87.64 | $20.39 |
| Average True Range (ATR) | 2.80 | 0.73 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 76.15 | 12.80 |
Stride Inc is an American online educational company. It offers alternative programs to traditional on-campus schooling. It also operates state-funded virtual charter schools around the United States. The educational programs for K-12 students are usually monitored by parents and provide virtual classroom environments where teachers meet with students online, by phone, or in-person. The company's contractual agreements with various school districts to offer its curriculum programs provide a majority of the company's revenue. The company lines of business are Managed Public School Programs, Institutional and Private Pay Schools and Other.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.